What DSIP is
DSIP is a naturally occurring nonapeptide discovered in 1974 that promotes delta wave sleep, reduces stress, and modulates multiple neurotransmitter systems including GABA and endogenous opioids. It has a molecular formula C35H48N10O15, mass 848.8 Da. Its published amino-acid sequence is Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. Common synonyms in the literature include Delta Sleep-Inducing Peptide, DSIP nonapeptide, and delta sleep peptide.
What it's studied for
Investigation of DSIP to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing DSIP spans Sleep architecture studies: EEG studies in rabbits, rats, and limited human cohorts show DSIP increases delta wave (slow-wave) sleep duration without suppressing REM sleep. Unlike benzodiazepines, it enhances physiological sleep patterns rather than altering them, Chronic insomnia trials: European clinical studies (primarily 1980s-1990s) in patients with chronic insomnia reported improved sleep onset latency, reduced nocturnal awakenings, and enhanced subjective sleep quality. Schneider-Helmert (1983) reported significant improvements in 15 of 16 patients with psychophysiological insomnia, and Stress and HPA axis: DSIP reduces ACTH and cortisol secretion, suggesting anxiolytic and stress-protective properties. Research in alcohol and opioid withdrawal contexts showed DSIP reduced withdrawal symptom severity and normalized stress hormone levels. Proposed mechanisms in the literature include GABA system enhancement and NMDA receptor interaction. None of this material describes therapeutic outcomes in humans, and BioInfinity does not sell, market, or provide dosing guidance for DSIP outside laboratory research.
Laboratory handling — storage and reconstitution
Lyophilized DSIP arrives as a fluffy off-white solid inside a sealed sterile vial. Because it ships as a small-molecule research compound, the powder is best stored between 2–8 °C prior to reconstitution and returned to −20 °C in aliquots for long-term storage post-reconstitution. Reconstitution is typically performed with bacteriostatic water (0.9 % benzyl alcohol preserved) rather than sterile water because the preservative extends solution stability once the vial has been punctured. Warming the reconstituted solution to room temperature before drawing helps redissolve any peptide that has settled against the vial wall. Avoid repeated freeze–thaw cycles: for peptides in this molecular-weight range (848.8 Da), freeze–thaw stress is one of the most common causes of loss-of-purity between batches.
How this batch is verified
Every batch of DSIP ships with a batch-specific Certificate of Analysis produced by an ISO-accredited third-party analytical laboratory. Reversed-phase HPLC confirms the assay against the expected 848.8 Da mass (C35H48N10O15); mass spectrometry validates the exact monoisotopic mass; endotoxin (LAL) testing confirms bacterial-contamination limits appropriate for laboratory research; and residual-solvent panels confirm the manufacturing pipeline. The lot number on the outer label matches the COA on the public /coa-library page — every purity claim is independently verifiable before you open the vial.
Related research
For the full mechanistic profile, published references, and constraint notes on DSIP, see the DSIP research page. All references cited on that page are peer-reviewed primary literature.
Research use only. DSIP is sold strictly for in-vitro and animal research. It is not a drug, food, supplement, or cosmetic and is not intended for human or veterinary consumption. No statements on this page describe or imply any therapeutic effect.
